These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9145977)

  • 21. Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.
    Oh WK; Kaplan ID; Febbo P; Prisby J; Manola J; Kaufman DS; Kantoff PW
    Am J Clin Oncol; 2003 Jun; 26(3):312-6. PubMed ID: 12796607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?
    Scolieri MJ; Altman A; Resnick MI
    J Urol; 2000 Nov; 164(5):1465-72. PubMed ID: 11025684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroendocrine cells in the prostatic carcinomas after neoadjuvant hormonal therapy.
    Chen X; Okada H; Gotoh A; Arakawa S; Kamidono S
    Kobe J Med Sci; 1997 Apr; 43(2):71-81. PubMed ID: 9385786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy.
    Minardi D; Galosi AB; Giannulis I; Montironi R; Polito M; Muzzonigro G
    Scand J Urol Nephrol; 2004; 38(1):19-25. PubMed ID: 15204422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer.
    Valicenti RK; Chervoneva I; Gomella LG
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1093-7. PubMed ID: 15001249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inference network-based analyses of the histopathological effects of androgen deprivation on prostate cancer.
    Montironi R; Santinelli A; Pomante R; Hamilton PW; Thompson D; Bartels PH
    J Pathol; 1999 Mar; 187(4):462-8. PubMed ID: 10398107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases.
    Bostwick DG; Qian J; Maihle NJ
    Prostate; 2004 Feb; 58(2):164-8. PubMed ID: 14716741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis.
    Marks RA; Zhang S; Montironi R; McCarthy RP; MacLennan GT; Lopez-Beltran A; Jiang Z; Zhou H; Zheng S; Davidson DD; Baldridge LA; Cheng L
    Prostate; 2008 Jun; 68(9):919-23. PubMed ID: 18409189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.
    Leibovich BC; Engen DE; Patterson DE; Pisansky TM; Alexander EE; Blute ML; Bergstralh EJ; Zincke H
    J Urol; 2000 Apr; 163(4):1178-82. PubMed ID: 10737490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
    Eaton CL; Wells JM; Holen I; Croucher PI; Hamdy FC
    Prostate; 2004 May; 59(3):304-10. PubMed ID: 15042606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
    Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
    J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer tissue is masked by bicalutamide: a case report.
    Ellinger J; Bastian PJ; Biermann K; Schmidt ME; Textor J; Bollmann D; Zhou H; Müller SC
    Eur J Med Res; 2007 May; 12(5):212-5. PubMed ID: 17513193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical changes in prostate cancer after androgen deprivation therapy.
    Bostwick DG
    Mol Urol; 2000; 4(3):101-6;discussion 107. PubMed ID: 11062363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
    Osunkoya AO; Hansel DE; Sun X; Netto GJ; Epstein JI
    Am J Surg Pathol; 2008 Mar; 32(3):461-7. PubMed ID: 18300803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
    Ali TZ; Epstein JI
    Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy.
    Kausik SJ; Blute ML; Sebo TJ; Leibovich BC; Bergstralh EJ; Slezak J; Zincke H
    Cancer; 2002 Sep; 95(6):1215-9. PubMed ID: 12216087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy.
    Hirano D; Okada Y; Minei S; Takimoto Y; Nemoto N
    Eur Urol; 2004 May; 45(5):586-92; discussion 592. PubMed ID: 15082200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.